275 results on '"Kilpatrick, E. S."'
Search Results
2. Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease
3. Postprandial effects of long-term niacin/laropiprant use on glucose and lipid metabolism and on cardiovascular risk in patients with polycystic ovary syndrome
4. Glucose variability does not contribute to the development of peripheral and autonomic neuropathy in type 1 diabetes: data from the DCCT
5. Use of complementary markers in assessing glycaemic control in people with diabetic kidney disease undergoing iron or erythropoietin treatment
6. Biological variation of cardiovascular risk factors in patients with diabetes
7. Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes
8. The effect of atorvastatin and simvastatin on vitamin D, oxidative stress and inflammatory marker concentrations in patients with type 2 diabetes: a crossover study
9. Polycystic ovary syndrome has no independent effect on vascular, inflammatory or thrombotic markers when matched for obesity
10. Implications of new European Union driving regulations on patients with Type 1 diabetes who participated in the Diabetes Control and Complications Trial
11. Short-term glucose variability in healthy volunteers is not associated with raised oxidative stress markers
12. Atorvastatin Improves 25OH Vitamin D Levels in Patients with Polycystic Ovary Syndrome.
13. Soy Phytoestrogens Precipitate Overt Hypothyroidism in Patients with Subclinical Hypothyroidism: A Randomized Double Blind Crossover Study.
14. The rise and fall of HbA1c as a risk marker for diabetes complications
15. Does severe hypoglycaemia influence microvascular complications in Type 1 diabetes? An analysis of the Diabetes Control and Complications Trial database
16. Use of complementary markers in assessing glycaemic control in patients with diabetes and chronic kidney disease undergoing iron or erythropoiesis stimulating agent treatment: A14 (P389)
17. The effect of extensive flooding in Hull on the glycaemic control of patients with diabetes
18. Metformin may maintain weight loss in obese patients with dysglycaemia initially treated with rimonabant
19. High-cocoa polyphenol-rich chocolate improves HDL cholesterol in Type 2 diabetes patients
20. For debate.Glucose variability and diabetes complication risk: we need to know the answer
21. Low density lipoprotein-cholesterol variability in patients with type 2 diabetes taking atorvastatin compared to simvastatin: justification for direct measurement?
22. Progression of impaired glucose regulation (IGR) to Type 2 diabetes: SD15 (P420)
23. New recommendations in diagnosis of diabetes mellitus from the Department of Health: comparing the old and new
24. Impaired fasting glucose and impaired glucose tolerance: follow-up rates over 2 years within a primary care setting
25. Intensive glucose therapy and clinical implications of recent data: a consensus statement from the Global Task Force on Glycaemic Control
26. HbA1c: ‘The old order changeth’
27. Elevated glycated haemoglobin is a strong predictor of mortality in patients with left ventricular systolic dysfunction who are not receiving treatment for diabetes mellitus
28. Exenatide initiation in type 2 diabetes: do more people discontinue treatment after individual rather than group starts?
29. The effect of glucose variability on the long-term risk of retinopathy in Type 1 diabetes: A21 (P525)
30. Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome
31. Haemoglobin A1c in the diagnosis and monitoring of diabetes mellitus
32. Variability of lipids in patients with Type 2 diabetes taking statin treatment: implications for target setting
33. Estimated average glucose (eAG): fit for purpose?
34. Biological variation of total testosterone, free androgen index and bioavailable testosterone in polycystic ovarian syndrome: implications for identifying hyperandrogenaemia
35. The effect of subject height on the long term risk of neuropathy in Type 1 diabetes: An analysis of the EDIC cohort: A46
36. The relationship between mean glucose and HbA1c in premenopausal women compared with males in the Diabetes Control and Complications Trial
37. Establishing pragmatic estimated GFR thresholds to guide metformin prescribing
38. Mean blood glucose compared to HbA1c in the prediction of cardiovascular disease in Type 1 diabetes: A61
39. Insulin resistance, the metabolic syndrome and complication risk in Type 1 diabetes: ‘double diabetes’ in the DCCT: A60
40. Improvement of glycaemic control with rebound following orlistat initiation and cessation associated with minimal weight change
41. Orlistat Is as Beneficial as Metformin in the Treatment of Polycystic Ovarian Syndrome
42. Evidence of gender bias when applying the new diagnostic criteria for myocardial infarction
43. HbA1c measurement
44. The Biological Variation of Testosterone and Sex Hormone-Binding Globulin (SHBG) in Polycystic Ovarian Syndrome: Implications for SHBG as a Surrogate Marker of Insulin Resistance
45. The Biological Variation of Insulin Resistance in Polycystic Ovarian Syndrome
46. Determinants of raised C-reactive protein concentration in type 1 diabetes
47. Concentration-Effect and Concentration-Toxicity Relations with Lamotrigine: A Prospective Study
48. P4475Glycated haemoglobin and risk of all-cause, causal mortality and cardiovascular hospitalisation in type 2 diabetes mellitus according to body mass index
49. Effect of soy on bone turn-over markers in men with type 2 diabetes and hypogonadism – a randomised controlled study
50. HbA1c Measurement
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.